All In Biotech

Drug Trial Radar · NCT03743896

Transdermal Delivery of Glucosamine to the Synovial Fluid of Male and Female With Knee Osteoarthritis

An Open Label, Single Dose, Bioavailability Study of Topical Transdermal Glucosamine Cream on the Synovial Fluid Tapped From Osteoarthritic Adult, Male and Female Human Subjects Already Undergoing Arthrocentesis

Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

240

Actual

Start

May 18, 2016

Primary completion

Mar 10, 2017

Study completion Mar 10, 2017

Sponsor

Lead sponsor
Lynk Biotechnologies Pte LtdIndustry
Sponsor type
Industry
Collaborators
T&T Family Health Clinic and Surgery, Singapore; Temasek Polytechnic School of Applied Science, Singapore
First posted
Nov 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 21 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glucosamine is commonly used as a treatment for Osteoarthritis (OA). While oral administration remains the most commonly used route, topical administration could offer numerous advantages such as targeted delivery to affected joints and overcoming the negative effects of the passage of the drug through the digestive system. The objective of this study is to assess the bioavailability of glucosamine in the synovial fluid of osteoarthritic joints, following the topical application of a commercially available transdermal glucosamine cream. Joint fluid samples will be collected from 2 groups of participants with knee OA: the Control group will not be subjected to any treatment while the Test group will apply 2g of transdermal glucosamine cream 1 to 3 hours before the joint fluid collection. Glucosamine concentration will be determined and the results obtained from both groups will be compared. This trial will potentially provide data to support that glucosamine can cross the skin and be delivered to the affected joint fluid when formulated in a transdermal cream base.

Conditions

  • Osteoarthritis, Knee

Interventions

  • Transdermal Glucosamine CreamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of glucosamine in synovial fluidTime frame: 1 to 3 hours post-intervention
  2. Concentration of glucosamine in synovial fluidTime frame: At baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • T&T Family Heath Clinic and Surgery

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.